Patients with NAFLD have reduced GLP-1 levels, and when used as a therapeutic approach, GLP-1 analogs have an indirect impact on hepatic metabolism, reducing hepatic steatosis, inflammation and, to a lesser extent, fibrosis [4,5]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.